Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302.

MLA

Kasai, Takashi, et al. “Phase I/II Study of Nedaplatin and Nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer: Kanto Respiratory Disease Study Group (KRSG) 1302.” International Journal of Clinical Oncology, vol. 27, no. 12, Dec. 2022, pp. 1841–48. EBSCOhost, https://doi.org/10.1007/s10147-022-02241-6.

APA

Kasai, T., Mori, K., Sugiyama, T., Koyama, N., Nakamura, Y., Ohyanagi, F., Fukuda, H., Hoshi, E., Kobayashi, K., & Nakayama, M. (2022). Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. International Journal of Clinical Oncology, 27(12), 1841–1848. https://doi.org/10.1007/s10147-022-02241-6

Chicago

Kasai, Takashi, Kiyoshi Mori, Tomohide Sugiyama, Nobuyuki Koyama, Yoichi Nakamura, Fumiyoshi Ohyanagi, Hiroki Fukuda, Eishin Hoshi, Kunihiko Kobayashi, and Mitsuo Nakayama. 2022. “Phase I/II Study of Nedaplatin and Nab-Paclitaxel for Patients with Previously Untreated Advanced Squamous Cell Lung Cancer: Kanto Respiratory Disease Study Group (KRSG) 1302.” International Journal of Clinical Oncology 27 (12): 1841–48. doi:10.1007/s10147-022-02241-6.